Jonathan M. Meyer (San Diego University of California), Stephen M. Stahl (San Diego University of California)
The Clozapine Handbook
Jonathan M. Meyer (San Diego University of California), Stephen M. Stahl (San Diego University of California)
The Clozapine Handbook
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses, but is underutilized partly due to clinician unfamiliarity with monitoring principles and side-effect management. This Handbook provides clinically focussed approaches and logic for clinicians to manage clozapine-treated patients.
Andere Kunden interessierten sich auch für
- Stephen M. StahlCase Studies: Stahl's Essential Psychopharmacology: Volume 282,99 €
- Christian RatschThe Encyclopedia of Psychoactive Plants103,99 €
- Edward Shorter (Professor of Psychiatry and Pr History of MedicineThe Rise and Fall of the Age of Psychopharmacology63,99 €
- Joel Paris (Montreal McGill University)Social Factors in the Personality Disorders29,99 €
- Jonathan M. Meyer (San Diego University of California)The Lithium Handbook50,99 €
- Rick StrassmanDmt: The Spirit Molecule15,99 €
- Mari J. WirfsThe Aprn and Pa's Complete Guide to Prescribing Drug Therapy 202262,99 €
-
-
-
Clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses, but is underutilized partly due to clinician unfamiliarity with monitoring principles and side-effect management. This Handbook provides clinically focussed approaches and logic for clinicians to manage clozapine-treated patients.
Produktdetails
- Produktdetails
- Stahl's Essential Psychopharmacology Handbooks
- Verlag: Cambridge University Press
- Seitenzahl: 326
- Erscheinungstermin: 16. Mai 2019
- Englisch
- Abmessung: 185mm x 121mm x 17mm
- Gewicht: 364g
- ISBN-13: 9781108447461
- ISBN-10: 1108447465
- Artikelnr.: 55293339
- Stahl's Essential Psychopharmacology Handbooks
- Verlag: Cambridge University Press
- Seitenzahl: 326
- Erscheinungstermin: 16. Mai 2019
- Englisch
- Abmessung: 185mm x 121mm x 17mm
- Gewicht: 364g
- ISBN-13: 9781108447461
- ISBN-10: 1108447465
- Artikelnr.: 55293339
Jonathan M. Meyer is currently a Clinical Professor of Psychiatry at the University of California, San Diego and a Psychopharmacology Consultant to the California Department of State Hospitals. Dr Meyer is an internationally recognised speaker on psychopharmacology and the treatment of severe mental illness, and is Distinguished Fellow of the American Psychiatric Association.
Preface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile
metabolism
kinetics
drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation
orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever
myocarditis
interstitial nephritis
DRESS
serositis and cardiomyopathy; 10. Eosinophilia
leukocytosis
thrombocytopenia
thrombocytosis
anemia
hepatic function abnormalities; 11. Managing enuresis and incontinence
priapism
venous thromboembolism
neuroleptic malignant syndrome
tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia
psychogenic polydipsia
treatment intolerant schizophrenia
suicidality
violence
mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients
elderly patients
patients with intellectual disability
pregnancy and risk for major congenital malformation
lactation
overdose
postmortem redistribution; Index.
metabolism
kinetics
drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation
orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever
myocarditis
interstitial nephritis
DRESS
serositis and cardiomyopathy; 10. Eosinophilia
leukocytosis
thrombocytopenia
thrombocytosis
anemia
hepatic function abnormalities; 11. Managing enuresis and incontinence
priapism
venous thromboembolism
neuroleptic malignant syndrome
tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia
psychogenic polydipsia
treatment intolerant schizophrenia
suicidality
violence
mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients
elderly patients
patients with intellectual disability
pregnancy and risk for major congenital malformation
lactation
overdose
postmortem redistribution; Index.
Preface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile
metabolism
kinetics
drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation
orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever
myocarditis
interstitial nephritis
DRESS
serositis and cardiomyopathy; 10. Eosinophilia
leukocytosis
thrombocytopenia
thrombocytosis
anemia
hepatic function abnormalities; 11. Managing enuresis and incontinence
priapism
venous thromboembolism
neuroleptic malignant syndrome
tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia
psychogenic polydipsia
treatment intolerant schizophrenia
suicidality
violence
mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients
elderly patients
patients with intellectual disability
pregnancy and risk for major congenital malformation
lactation
overdose
postmortem redistribution; Index.
metabolism
kinetics
drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation
orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever
myocarditis
interstitial nephritis
DRESS
serositis and cardiomyopathy; 10. Eosinophilia
leukocytosis
thrombocytopenia
thrombocytosis
anemia
hepatic function abnormalities; 11. Managing enuresis and incontinence
priapism
venous thromboembolism
neuroleptic malignant syndrome
tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia
psychogenic polydipsia
treatment intolerant schizophrenia
suicidality
violence
mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients
elderly patients
patients with intellectual disability
pregnancy and risk for major congenital malformation
lactation
overdose
postmortem redistribution; Index.